Linagliptin: A novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor

Current Drug Targets

Volumn 13, Issue 7, 2012, Pages 970-983

  Agrawal, Ritesh ^a   Jain, Pratima ^a   Dikshit, S N ^a  

^a GOVERNMENT SCIENCE COLLEGE   (India)

Author keywords

Approval; BI 1356; BI 1356 BS; Boehringer ingelheim and lilly; DDP IV; Diabetes type II; Dipeptidyl peptidase IV; Emerging target; GIP; Gliptins; GLP 1; Linagliptin; Methylxanthines; NIDDM; Non insulin dependent diabetes mellitus; Ondero; Tradjenta; Trajenta

Indexed keywords

ALOGLIPTIN; BI 356; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; LINAGLIPTIN; M 473; METFORMIN; MOXIFLOXACIN; PIOGLITAZONE; PLACEBO; RIFAMPICIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

AREA UNDER THE CURVE; COMPARATIVE STUDY; CRYSTAL STRUCTURE; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GERIATRIC CARE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEART ELECTROPHYSIOLOGY; HUMAN; HYPOGLYCEMIA; IC 50; INSULIN RELEASE; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATENT; PHARMACOPHORE; PREGNANCY; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

EID: 84861704671     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800675731     Document Type: Review

References (44)

1. Executive Summary. indd. Available at: http://www.google. co.in/url?sa=t&source=web&cd=1&ved= 0CBcQFjAA&url=http%3A%2F%2FError! Hyperlink reference not valid. [accessed July 13, 2011].
2. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Available at: Part 1. Diagnosis and classification of diabetes mellitus. Available at: http://www. who.int/diabetes/publications/en/ [accessed July 13, 2011].
3. Pratley RE, Salsali A. Inhibition of DPP-IV: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007; 23(4): 919-31.
4. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328(2): 556-63.
5. Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes mellitus. NPS RADAR. August 1, 2010. Available at: http://www.nps.org.au/health_professionals/publications/nps_radar/ 2008/august_ 2008/aug_2010_gliptins [accessed August 6, 2010].
6. Masur K, Schwartz F, Entschladen F, Niggemann B, Zaenker KS. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept 2006;137(3): 147-55.
7. Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004; 19(4): 1345-51.
8. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res 2005; 65(4): 1325-34.
9. Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetic Patients That Cannot Control Their Diabetes on Metformin Alone (Synergy 104). Available at: http://clinicaltrials.gov/ct2/show/ NCT00995345 [accessed July 13, 2011].
10. Galvus (vildagliptin)-DPP-IV Inhibitor / Oral Antidiabetic Agent. Available at: http://www.drugdevelopment-technology.com/ projects/vildagliptin/ [accessed July 13, 2011].
11. Januvia. Available at: http://www.rxlist.com/januvia-drug.htm [accessed July 13, 2011].
12. Januvia(sitagliptin phosphate). Available at: http://www. medilexicon.com/drugs/januvia.php [accessed July 13, 2011].
13. Diabetes-Pipeline Review, Q1 2011. Available at: http:// marketpublishers.com/report/ medicine_pharmaceuticals_biotechnology/drugs_biotechnology/dia betes_pipeline_review_q1_2011.html [accessed July 13, 2011].
14. Anti-Diabetes. Available at: http://www.euroasiarnd.com/ productdetail-Alogliptin-Benzoate-ANTI-DIABETES-5906-23.html [accessed July 13, 2011].
15. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with Linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13(7): 653-61.
16. Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetic Patients That Cannot Control Their Diabetes on Metformin Alone (Synergy 104). Available at: http://clinicaltrials.gov/ct2/show/ NCT00995345 [accessed July 13, 2011].
17. Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials. Available at: http://www.bioportfolio.com/ news/article/56064/Glenmark-s-Novel-Molecule-For-Diabetes-Melogliptin-To-Enter-Phase-Iii-Trials.html [accessed July 13, 2011].
18. The Effects of SK-0403, a Highly Selective DPP-IV Inhibitor, on the Amelioration of Glucose Intolerance in Haploinsufficiency of Glucokinase Mice on a High-Fat Diet. Available at: http://ww2.aievolution.com/ada1101/index.cfm?do=abs.viewAbs& abs=12012 [accessed July 13, 2011].
19. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008. Available at: http://www.rxtimes.com/fda-acceptsinvestigational-new-drug-application-for-ari-2243-and-a-first-inman-clinical-trial-set-to-begin-during-the-first-half-of-2008/ [accessed July 13, 2011].
20. Alantos initiates Phase I study for DPP-IV diabetes drug. Available at: http://www.outsourcing-pharma.com/Preclinical-Research/ Alantos-initiates-Phase-I-study-for-DPP-IV-diabetes-drug [accessed July 13, 2011].
21. DB160. Available at: http://www.darabio.com/DB160.htm [accessed July 13, 2011].
22. Cho JM, Jang HW, Cheon H, et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis. Diabetes Res Clin Pract 2011; 91(1): 72-9.
23. Diabetes & Health: ALOGLIPTIN-ONE MORE EXPECTED Available at: http://www.google.co.in/url?sa=t&source=web&cd =5&ved=0CDgQFjAE&url=http%3A%2F%2Friyazsheena.blogspo t.com%2F2010%2F12%2Falogliptin-one-more-expectedhtml& rct=j&q=Gemigliptin %2C%20diabetes&ei=XT4dToGhJM6srAelm92iDA&usg= AFQjCNFP6qK3XbEnAFCsaFpzgMeAc8cDGg&sig2=bDFjRoBY CioBvG7wCaSmbg&cad=rja [accessed July 13, 2011].
24. Furuta Y, Horiguchi M, Sugaru E, et al. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice. Diabetes Obes Metab 2010; 12(5): 421-30.
25. FDA approves Linagliptin tablets for the treatment of type 2 diabetes. Available at: http://www.boehringeringelheim.com/news/ news_releases/press_releases/2011/03_may_2011_diabetes.html [accessed July 13, 2011].
26. FDA Approves Tradjenta™ (Linagliptin) Tablets for the Treatment of Type 2 Diabetes. Available at: https://investor. lilly.com/releasedetail2.cfm?ReleaseID=573835 [accessed July 13, 2011].
27. Available at: http://www.worldpharmanews.com/boehringeringelheim/ 1667-fda-approves-Linagliptin-tablets-for-the-treatmentof-type-2-diabetes [accessed July 13, 2011].
28. USFDA. Products on Application (NDA) 201280. Available at: http://www.accessdata.fda.gov /scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [accessed July 13, 2011].
29. Himmelsbach F, Langkopf E, Eckhardt M, et al. U.S. Patent 7407955, August 12, 2003.
30. SIEGER Peter, Kemmer Dirk, Kohlbauer Peter, Nicola Thomas, Renz Mart U.S. Patent application 20070259900A1, May 4, 2007.
31. Pfrengle Waldemar, Pachur Thorsten, Nicola Thomas, Duran Adil. U.S. Patent 7820815, November 4, 2005.
32. US Patent Office. Available at: http://patft.uspto.gov/[accessed June 01, 2011].
33. Europe patent office. Available at: http://worldwide.espacenet. com/numberSearch?locale=en_EP [accessed June 01, 2011].
34. WIPO-World Intellectual Property Organization. Available at: http://www.wipo.int//portal/index.html.en [accessed June 01, 2011].
35. Van der Veken P, Haemers A, Augustyns K. Prolyl peptidase related to dipeptidyl peptidase IV: Potential of specific inhibitors in drug discovery, Curr Topics Med Chem 2007; 7(6): 621-35.
36. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325(1): 175-82.
37. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2007; 50(26): 6450-3.
38. Center for drug evaluation and research, application number: 201280, Pharmacology review(s), Available at: www.accessdata. fda.gov/drugsatfda_docs/./201280Orig1s000PharmR.pdf [accessed August 31, 2011].
39. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008; 325(1): 175-82.
40. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010; 19(1): 133-40.
41. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328(2): 556-63.
42. DPP-IV INHIBITORS-Dipeptidyl peptidase-4 inhibitor-Gliptins. Available at: http://www.globalrph.com/DPP-IV-inhibitors.htm [accessed July 13, 2011].
43. TRADJENTA (Linagliptin) tablet, film coated [Boehringer Ingelheim Pharmaceuticals, Inc.]. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=43604 [accessed July 13, 2011].
44. 1. Available at: https://online.epocrates.com/u/1c76069/ Tradjenta/Monotherapy [accessed July 13, 2011].